Follow Health Care Reform Insider on Twitter
You are here:  Home  >  Emerging Healthcare Models  >  Current Article

Amgen strikes Enbrel ‘outcomes’ contract with Harvard Pilgrim

February 24, 2017 

Evan as biosimilar competition for Amgen’s blockbuster rheumatoid arthritis drug Enbrel is lurking in the background, the biotech may have found a way to preserve market share with an outcomes-based contract for the popular med.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>